Publications
Found 6 results
Filters: Author is F.M. Peria [Clear All Filters]
“Combination of microRNA-21 expression with the serum marker CA19-9 increases the accuracy of diagnosis of pancreatic adenocarcinoma”, Genetics and Molecular Research, vol. 19, no. 4, 2020.
, “Tissue and serum expression of microRNAs miR-34a, miR-143, miR-145 and miR-335 is not correlated with tumor progression in meningiomas”, Genetics and Molecula Research, vol. 19, no. 2, 2020.
, “Expression of microRNAs miR-126 and miR-873 and genes CASPASE-8 and C-FLIP in neurospheres of Glioblastoma lines U-343 subjected to treatment with ionizing radiation and temozolomide.”, Genetics and Molecular Research, vol. 18, no. 4, 2019.
, “Expression of oncogenic microRNA-21 in neurospheres and attached cells of a glioblastoma cell line increased after treatment with temozolomide and ionizing radiation”, Genetics and Molecular Research, vol. 18, no. 2, 2019.
, “Gene expression study related with the intrinsic pathway of apoptosis in bladder cancer by real-time PCR technique”, vol. 12, pp. 878-886, 2013.
, Ameisen JC (2002). On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ. 9: 367-393.
http://dx.doi.org/10.1038/sj.cdd.4400950
PMid:11965491
Ashkenazi A and Dixit VM (1998). Death receptors: signaling and modulation. Science 281: 1305-1308.
http://dx.doi.org/10.1126/science.281.5381.1305
PMid:9721089
Bilim VN, Tomita Y, Kawasaki T, Takeda M, et al. (1998). Variable Bcl-2 phenotype in benign and malignant lesions of urothelium. Cancer Lett. 128: 87-92.
http://dx.doi.org/10.1016/S0304-3835(98)00055-X
Bilim V, Kasahara T, Hara N, Takahashi K, et al. (2003). Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int. J. Cancer 103: 29-37.
http://dx.doi.org/10.1002/ijc.10776
PMid:12455050
Budihardjo I, Oliver H, Lutter M, Luo X, et al. (1999). Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15: 269-290.
http://dx.doi.org/10.1146/annurev.cellbio.15.1.269
PMid:10611963
Christoph F, Hinz S, Kempkensteffen C, Weikert S, et al. (2007). A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer. J. Cancer Res. Clin. Oncol. 133: 343-349.
http://dx.doi.org/10.1007/s00432-006-0174-9
PMid:17160380
Christoph F, Hinz S, Weikert S, Kempkensteffen C, et al. (2008). Comparative promoter methylation analysis of p53 target genes in urogenital cancers. Urol. Int. 80: 398-404.
http://dx.doi.org/10.1159/000132698
PMid:18587251
Cory S and Adams JM (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2: 647-656.
http://dx.doi.org/10.1038/nrc883
PMid:12209154
Deveraux QL and Reed JC (1999). IAP family proteins - suppressors of apoptosis. Genes Dev. 13: 239-252.
http://dx.doi.org/10.1101/gad.13.3.239
PMid:9990849
Deveraux QL, Leo E, Stennicke HR, Welsh K, et al. (1999). Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 18: 5242-5251.
http://dx.doi.org/10.1093/emboj/18.19.5242
PMid:10508158 PMCid:1171595
Fu WN, Bertoni F, Kelsey SM, McElwaine SM, et al. (2003). Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 22: 451-455.
http://dx.doi.org/10.1038/sj.onc.1206147
PMid:12545166
Furukawa Y, Sutheesophon K, Wada T, Nishimura M, et al. (2005). Methylation silencing of the Apaf-1 gene in acute leukemia. Mol. Cancer Res. 3: 325-334.
http://dx.doi.org/10.1158/1541-7786.MCR-04-0105
PMid:15972851
Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100: 57-70.
http://dx.doi.org/10.1016/S0092-8674(00)81683-9
Hinz S, Kempkensteffen C, Weikert S, Schostak M, et al. (2007). EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. Tumour. Biol. 28: 151-157.
http://dx.doi.org/10.1159/000103380
PMid:17541304
Jia L, Srinivasula SM, Liu FT, Newland AC, et al. (2001). Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 98: 414-421.
http://dx.doi.org/10.1182/blood.V98.2.414
PMid:11435311
King ED, Matteson J, Jacobs SC and Kyprianou N (1996). Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J. Urol. 155: 316-320.
http://dx.doi.org/10.1016/S0022-5347(01)66652-7
Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136.
http://dx.doi.org/10.1126/science.275.5303.1132
PMid:9027315
Li K, Li Y, Shelton JM, Richardson JA, et al. (2000). Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis. Cell 101: 389-399.
http://dx.doi.org/10.1016/S0092-8674(00)80849-1
Li M, Song T, Yin ZF and Na YQ (2007). XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin. Med. J. 120: 469-473.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, et al. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489.
http://dx.doi.org/10.1016/S0092-8674(00)80434-1
Liu X, Kim CN, Yang J, Jemmerson R, et al. (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147-157.
http://dx.doi.org/10.1016/S0092-8674(00)80085-9
Nakanishi K, Tominaga S, Kawai T, Torikata C, et al. (1998). Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Arch. 432: 445-450.
http://dx.doi.org/10.1007/s004280050189
PMid:9645444
Newmeyer DD, Farschon DM and Reed JC (1994). Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79: 353-364.
http://dx.doi.org/10.1016/0092-8674(94)90203-8
Ohl F, Jung M, Radonic A, Sachs M, et al. (2006). Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J. Urol. 175: 1915-1920.
http://dx.doi.org/10.1016/S0022-5347(05)00919-5
Ow YP, Green DR, Hao Z and Mak TW (2008). Cytochrome c: functions beyond respiration. Nat. Rev. Mol. Cell Biol. 9: 532-542.
http://dx.doi.org/10.1038/nrm2434
PMid:18568041
Parkin DM, Bray F, Ferlay J and Pisani P (2001a). Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94: 153-156.
http://dx.doi.org/10.1002/ijc.1440
PMid:11668491
Parkin DM, Bray FI and Devesa SS (2001b). Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37 (Suppl 8): S4-66.
http://dx.doi.org/10.1016/S0959-8049(01)00267-2
Parton M, Krajewski S, Smith I, Krajewska M, et al. (2002). Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin. Cancer Res. 8: 2100-2108.
PMid:12114409
Pashos CL, Botteman MF, Laskin BL and Redaelli A (2002). Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 10: 311-322.
http://dx.doi.org/10.1046/j.1523-5394.2002.106011.x
PMid:12406054
Raff M (1998). Cell suicide for beginners. Nature 396: 119-122.
http://dx.doi.org/10.1038/24055
PMid:9823889
Reed JC, Miyashita T, Takayama S, Wang HG, et al. (1996). BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem. 60: 23-32.
http://dx.doi.org/10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5
Riedl SJ and Shi Y (2004). Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 5: 897-907.
http://dx.doi.org/10.1038/nrm1496
PMid:15520809
Salvesen GS and Duckett CS (2002). IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3: 401-410.
http://dx.doi.org/10.1038/nrm830
PMid:12042762
Shi Y (2002). Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9: 459-470.
http://dx.doi.org/10.1016/S1097-2765(02)00482-3
Shiina H, Igawa M, Urakami S, Honda S, et al. (1996). Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J. Clin. Pathol. 49: 395-399.
http://dx.doi.org/10.1136/jcp.49.5.395
PMid:8707954 PMCid:500479
Soengas MS, Capodieci P, Polsky D, Mora J, et al. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211.
http://dx.doi.org/10.1038/35051606
PMid:11196646
Strasser A, Harris AW, Bath ML and Cory S (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
http://dx.doi.org/10.1038/348331a0
PMid:2250704
Takeuchi H, Kim J, Fujimoto A, Umetani N, et al. (2005). X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin. Cancer Res. 11: 7621-7628.
http://dx.doi.org/10.1158/1078-0432.CCR-05-0479
PMid:16278380
Zhivotovsky B, Orrenius S, Brustugun OT and Doskeland SO (1998). Injected cytochrome c induces apoptosis. Nature 391: 449-450.
http://dx.doi.org/10.1038/35060
PMid:9461210
Zou H, Henzel WJ, Liu X, Lutschg A, et al. (1997). Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413.
http://dx.doi.org/10.1016/S0092-8674(00)80501-2
“Osteosarcoma arising from osteochondroma of the tibia: case report and cytogenetic findings”, vol. 11. pp. 448-454, 2012.
, Bovée JV, Cleton-Jansen AM, Wuyts W, Caethoven G, et al. (1999). EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am. J. Hum. Genet. 65: 689-698.http://dx.doi.org/10.1086/302532PMid:10441575Bovée JV, Sakkers RJ, Geirnaerdt MJ, Taminiau AH, et al. (2002). Intermediate grade osteosarcoma and chondrosarcoma arising in an osteochondroma. A case report of a patient with hereditary multiple exostoses. J. Clin. Pathol. 55: 226- 229.http://dx.doi.org/10.1136/jcp.55.3.226PMid:11896078 PMCid:1769605Garrison RC, Unni KK, McLeod RA, Pritchard DJ, et al. (1982). Chondrosarcoma arising in osteochondroma. Cancer 49: 1890-1897.http://dx.doi.org/10.1002/1097-0142(19820501)49:9<1890::AID-CNCR2820490923>3.0.CO;2-UKhurana J, Abdul-Karim F and Bovée JVMG (2002). Osteochondroma. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone (Fletcher CDM, Unni KK and Mertens F, eds.). IARC Press, Lyon, 234-236.Lamovec J, Spiler M and Jevtic V (1999). Osteosarcoma arising in a solitary osteochondroma of the fibula. Arch. Pathol. Lab. Med. 123: 832-834.PMid:10458834Lee KC, Davies AM and Cassar-Pullicino VN (2002). Imaging the complications of osteochondromas. Clin. Radiol. 57: 18-28.http://dx.doi.org/10.1053/crad.2001.0719PMid:11798198Meissner SA, Vieth V, August C and Winkelmann W (2006). Radiology-pathology conference: osteosarcoma in a cartilaginous exostosis of the femur. Clin. Imaging 30: 206-209.http://dx.doi.org/10.1016/j.clinimag.2005.12.026PMid:16632158Mertens F, Rydholm A, Kreicbergs A, Willen H, et al. (1994). Loss of chromosome band 8q24 in sporadic osteocartilaginous exostoses. Genes Chromosomes Cancer 9: 8-12.http://dx.doi.org/10.1002/gcc.2870090103Nezhad ST, Bagheri MH and Rakhshandero SH (2008). Osteosarcoma arising from a solitary osteochondroma of the tibia. IRCMJ 10: 341-343.Nishida Y, Isu K, Ueda T, Nishimoto Y, et al. (2009). Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group. J. Surg. Oncol. 100: 48-54.http://dx.doi.org/10.1002/jso.21287PMid:19384906Nojima T, Yamashiro K, Fujita M, Isu K, et al. (1991). A case of osteosarcoma arising in a solitary osteochondroma. Acta Orthop. Scand. 62: 290-292.http://dx.doi.org/10.3109/17453679108993613Sandberg AA and Bridge JA (2003). Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet. Cytogenet. 145: 1-30.http://dx.doi.org/10.1016/S0165-4608(03)00105-5Shaffer LG and Tommerup N (2005). ISCN 2005: An International System for Human Cytogenetic Nomenclature. Karger, Basel.Sjögren H, Orndal C, Tingby O, Meis-Kindblom JM, et al. (2004). Cytogenetic and spectral karyotype analyses of benign and malignant cartilage tumours. Int. J. Oncol. 24: 1385-1391.PMid:15138578Staals EL, Bacchini P, Mercuri M and Bertoni F (2007). Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J. Bone Joint. Surg. Am. 89: 987-993.http://dx.doi.org/10.2106/JBJS.F.00288PMid:17473135Zuntini M, Pedrini E, Parra A, Sgariglia F, et al. (2010). Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation. Oncogene 29: 3827-3834.http://dx.doi.org/10.1038/onc.2010.135PMid:20418910